Plasma and kidney angiotensin II levels and renal functional responses to AT(1) receptor blockade in hypertensive Ren-2 transgenic rats
Language English Country Netherlands Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
15126925
DOI
10.1097/00004872-200404000-00026
PII: 00004872-200404000-00026
Knihovny.cz E-resources
- MeSH
- Angiotensin II blood metabolism MeSH
- Angiotensin Receptor Antagonists * MeSH
- Antihypertensive Agents pharmacology MeSH
- Benzimidazoles pharmacology MeSH
- Biphenyl Compounds MeSH
- Animals, Genetically Modified genetics MeSH
- Glomerular Filtration Rate drug effects MeSH
- Hypertension genetics metabolism MeSH
- Rats MeSH
- RNA, Messenger genetics metabolism MeSH
- Rats, Sprague-Dawley MeSH
- Receptor, Angiotensin, Type 1 metabolism MeSH
- Renal Plasma Flow drug effects MeSH
- Sodium urine MeSH
- Tetrazoles pharmacology MeSH
- Kidney Function Tests MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Angiotensin II MeSH
- Angiotensin Receptor Antagonists * MeSH
- Antihypertensive Agents MeSH
- Benzimidazoles MeSH
- Biphenyl Compounds MeSH
- candesartan MeSH Browser
- RNA, Messenger MeSH
- Receptor, Angiotensin, Type 1 MeSH
- Sodium MeSH
- Tetrazoles MeSH
OBJECTIVE: The first aim of the present study was to assess plasma and kidney angiotensin II (ANG II) levels and renal cortical ANG II receptor subtype 1A (AT1A) mRNA expression in hypertensive Ren-2 transgenic rats (TGR) and in normotensive Hannover Sprague-Dawley (HanSD) rats. The second aim was to investigate potential differences between TGR and HanSD in blood pressure (BP) and renal functional responses to either intravenous (i.v.), i.e. systemic, or intrarenal (i.r.) AT1 receptor blockade with candesartan. METHODS: Rats were anesthetized and prepared for clearance experiments. In series 1, ANG II concentrations were assayed by radioimmunoassay and renal cortical AT1A mRNA expression by semiquantitative reverse transcriptase-polyacrylamide gel electrophoresis. In series 2, BP and renal functional responses were evaluated after either i.v. or i.r. bolus administration of candesartan. RESULTS: Plasma and kidney ANG II levels were significantly lower in TGR than in HanSD (39 +/- 5 versus 107 +/- 19 fmol/ml and 251 +/- 41 versus 571 +/- 95 fmol/g, respectively, P < 0.05). Renal AT1A mRNA expression was not different between TGR and HanSD. Intravenous candesartan caused comparable decreases in BP in TGR and HanSD and did not change renal plasma flow (RPF) or absolute and fractional sodium excretion in HanSD. In contrast, i.v. candesartan significantly increased RPF (+27 +/- 6%, P < 0.05) and absolute and fractional sodium excretion (+49 +/- 10 and + 42 +/- 9%, respectively P < 0.05) in TGR without changing glomerular filtration rate (GFR). Acute i.r. candesartan increased RPF by +36 +/- 6% (P < 0.05) in TGR but not in HanSD with a greater rise in absolute and fractional sodium excretion in TGR (+124 +/-8 and 97 +/- 9%, respectively) than in HanSD (+81 +/- 9 and +69 +/- 8%, respectively) (P < 0.05). CONCLUSIONS: The enhanced responses of RPF and sodium excretion to AT1 receptor blockade in TGR suggest that renal hemodynamics and sodium excretion in TGR are under strong ANG II influence. The compromised ability of the kidney to respond to BP elevations by appropriate increases in sodium excretion may contribute to the maintenance of high BP in TGR. Thus, the present findings provide new insights into the pathophysiology of hypertension in this model.
References provided by Crossref.org
Research on Experimental Hypertension in Prague (1966-2009)